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Metformin treatment is associated with a decreased
risk and better prognosis of pancreatic cancer (PC) in
patients with type 2 diabetes, but the mechanism of
metformin’s PC growth inhibition in the context of a pre-
diabetic state is unknown. We used a Panc02 pancreatic
tumor cell transplant model in diet-induced obese (DIO)
C57BL/6 mice to compare the effects of metformin and
the direct mammalian target of rapamycin (mTOR) in-
hibitor rapamycin on PC growth, glucose regulation,
mTOR pathway signaling, and candidate microRNA
(miR) expression. In DIO/prediabetic mice, metformin
and rapamycin significantly reduced pancreatic tumor
growth and mTOR-related signaling. The rapamycin
effects centered on decreased mTOR-regulated growth
and survival signaling, including increased expression of
let-7b and cell cycle–regulating miRs. Metformin (but
not rapamycin) reduced glucose and insulin levels and
expression of miR-34a and its direct targets Notch, Slug,
and Snail. Metformin also reduced the number and size
of Panc02 tumor spheres in vitro and inhibited the ex-
pression of Notch in spheroids. Our results suggest that
metformin and rapamycin can both inhibit pancreatic
tumor growth in obese, prediabetic mice through shared
and distinct mechanisms. Metformin and direct mTOR
inhibitors, alone or possibly in combination, represent
promising intervention strategies for breaking the
diabetes-PC link.
Type 2 diabetes (T2D) is a progressive metabolic disorder
affecting nearly 30 million Americans (;9.3% of the
population) and is associated with obesity and increased
risk of developing and dying from cancer (1). More spe-
cifically, the risk of developing pancreatic cancer (PC) is
twice that of the nondiabetic population (2,3). Prediabe-
tes, defined as having elevated fasting glucose and im-
paired glucose tolerance, is rising in prevalence even
faster than T2D, with nearly 90 million prediabetic
Americans (including 51% of Americans .65 years of
age) (1). This is of particular concern regarding PC since
.80% of PC cases develop after age 60 (2). Putative
mechanistic explanations for the link between prediabe-
tes, T2D, and PC include chronic hyperinsulinemia, oxi-
dative stress, and inflammation (4).
Epidemiologic studies suggest that metformin,
a widely used drug for the treatment of T2D (5), is asso-
ciated with reduced risk among patients with diabetes of
being either diagnosed with, or dying from, PC (6–8).
However, whether these associations reflect a genuine
protective action of metformin, as compared with other
antidiabetic drugs, or whether they are the result of con-
founding (since T2D patients prescribed metformin may
have very different clinical characteristics than T2D
patients taking sulfonylurea or other glucose-lowering
medications), remains unclear (9,10). Moreover, the
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potential PC chemoprotective effects of metformin are not
well understood.
Metformin can diminish hepatic glucose output,
resulting in improved insulin sensitivity; it can also exert
direct effects on tumor cell signaling (11,12). Direct cel-
lular effects of metformin involve inhibition of ATP pro-
duction, increased AMP kinase (AMPK) activity (13), and
inhibition of the mammalian target of rapamycin (mTOR), a
complex that couples protein synthesis to external growth
factors and intracellular energy stores (14). Recent evi-
dence indicates that this effect on mTOR is accomplished
through transcription factor, Sp1-mediated downregula-
tion of IGF-1 signaling (12). Inhibition of mTOR decreases
cell proliferation in several cancer cell lines, including PC
cells (12,15).
Rapamycin, a specific mTOR inhibitor, inhibits several
processes involved in tumor cell proliferation and survival
(16,17). Despite their shared mTOR inhibitory effects,
rapamycin and metformin differentially influence other
targets, including several microRNAs (miRs), noncoding
RNA molecules that posttranscriptionally regulate gene
expression (18). miRs regulate cellular processes involved
in cancer initiation, recurrence, and metastasis (19).
To our knowledge, a direct comparison between the
effects of metformin and rapamycin on PC outcomes in
the context of diet-induced obesity (DIO) and prediabe-
tes has not yet been reported. We chose to use a model
of prediabetes characterized by hyperglycemia and in-
sulin resistance since prediabetes is an established risk
factor for PC (1), and people with prediabetes are be-
coming more prevalent in the U.S. and represent an
important population for cancer prevention and treat-
ment. The aim of this study was to compare metformin
and rapamycin with respect to PC growth, systemic glu-
cose metabolism, mTOR pathway signaling, candidate
miR expression, and cancer stem cell (CSC) and epithe-
lial-to-mesenchymal transition (EMT) characteristics us-
ing a syngeneic murine PC transplant model in DIO/
prediabetic mice.
RESEARCH DESIGN AND METHODS
Mice, Diet, and Experimental Design
Mice were singly housed in a semibarrier facility in the
Animal Resource Center at The University of Texas; the
Institutional Animal Care and Use Committee approved
all experimentation.
Seventy-five male 6-week-old C57BL/6 mice (The
Jackson Laboratory, Bar Harbor, ME) were administered a
DIO diet (D12492; Research Diets) throughout the study.
After 15 weeks of DIO, mice were randomized (25 per
group) to receive either 1) metformin (250 mg/kg continu-
ously in drinking water), 2) rapamycin (2.5 mg/kg, admin-
istered i.p. every other day; LC Laboratories, Woburn, MA),
or 3) vehicle control (0.1% DMSO, in 0.9% saline, i.p. every
other day) for 5 weeks. The metformin group received
vehicle injections every other day, whereas the rapamycin
and vehicle control groups were provided ad libitum access
to drinking water without metformin. The rapamycin dose
of 2.5 mg/kg was chosen to achieve inhibition of phosphor-
ylation of mTOR based on our previous studies (20). At
week 19 on study (4 weeks of drug treatment), 10 mice
per group underwent glucose tolerance test and insulin
tolerance test (as previously described [20,21]) and then
were killed and their tissues collected and stored. At 20
weeks on study, the remaining mice (n = 15 per group)
were injected (subcutaneously) in the right flank with 5 3
105 Panc02 murine PC cells (maintained in McCoy’s media
as previously described [22]) and continued on their diet
regimen for an additional 4 weeks while tumor growth was
monitored. Food intake and body weights were recorded
weekly. At study termination (week 24), all mice were fasted
for 6 h and anesthetized by CO2 inhalation and then blood
was collected via cardiac puncture. Blood samples were
centrifuged at 9,300g for 5 min and serum collected and
stored at280°C. Pancreatic tumors were either snap frozen
in liquid nitrogen and stored at 280°C or fixed with 10%
neutral-buffered formalin overnight, paraffin embedded,
and used for histologic and immunohistochemical analyses
as described below.
Serum Hormones and Adipokines
Serum insulin, IGF-1, resistin, and adiponectin concen-
trations were measured in mice (vehicle, n = 11; met-
formin, n = 14; rapamycin, n = 14) using a LINCOplex
bead-based array assay (Millipore Corporation, Billerica,
MA) on a Bio-Rad Bio-Plex multianalyte detection system
(Bio-Rad, Hercules, CA) according to the manufacturers’
directions.
Histopathology and Immunohistochemistry
Formalin-fixed pancreatic tumors were embedded in
paraffin, cut into 4-mm sections, and processed for ei-
ther hematoxylin and eosin or immunohistochemical
staining at the Histology Core Laboratory at The Univer-
sity of Texas MD Anderson Cancer Center (Smithville,
TX). Antibodies used for immunohistochemical analyses
were optimized using both positive and negative con-
trols. Slides were deparaffinized and sequentially hy-
drated in ethanol and water. Antigen retrieval was
achieved by microwaving slides for 10 min in 10
mmol/L citrate buffer. Endogenous peroxidase was
quenched with 3% hydrogen peroxide for 10 min. Non-
specific binding was inhibited with Biocare blocking re-
agent (Biocare Medical, Concord, CA) for 30 min at room
temperature followed by incubation with primary anti-
bodies (previously described [20]) diluted in blocking
buffer. Slides were washed five times with PBS and de-
veloped with diaminobenzidine followed by hematoxylin
counterstain.
For each immunohistochemical marker, randomly selected
slides (eight mice per group) were digitized using the Aperio
ScanScope System (ScanScope XT; Aperio Technologies, Vista,
CA). Analysis of immunohistochemically stained tumor sec-
tions was performed on four fields per slide using the
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standard ImageScope membrane/cytoplasmic-specific
algorithms to quantify the percentage of cells stained
positive for pAkt, pmTOR, pACC, cyclin D1, and cdk4 (cdk4,
control, and metformin groups had n = 7).
Gene Expression Analysis
RNA was extracted from untreated and treated pancreatic
tumor spheres (n = 3 per group) and tumor tissue (n = 6
per group) using TRI Reagent (Sigma-Aldrich, St. Louis,
MO) according to the manufacturer’s instructions. Com-
plimentary DNA was synthesized from extracted RNA
using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA) according to the
manufacturer’s directions. For miR analysis, cDNA was
synthesized using TaqMan MicroRNA Reverse Transcrip-
tion Kit (Applied Biosystems). Gene expression for EMT
and miRs was measured by quantitative real-time PCR
using TaqMan gene expression assays with TaqMan Uni-
versal PCR Master Mix (Applied Biosystems) on an Applied
Biosystems ViiA 7 Real-Time PCR System. Expression data
for mRNA were normalized to the housekeeping gene,
b-actin, whereas miR expression levels were normalized
to miR-16 expression. Relative quantitation (RQ) was cal-
culated using the DDCt method.
Notch1 Luciferase Assay
Luciferase assays were performed to assess whether
miR-34a targets the Notch 39 untranslated region (UTR)
in Panc02 cells using LightSwitch 39 UTR Reporter
GoClones, LightSwitch miR mimics, LightSwitch Assay
regents, and associated protocols (SwitchGear Genomics,
Menlo Park, CA). The experiment was repeated three in-
dependent times, and data are presented as mean 6 SEM.
The mutant Notch1 39 UTR vector was generated from
LightSwitch Notch1 39 UTR GoClone vector DNA (Switch-
Gear Genomics) using the QuikChange Lightning Multi
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA) according to the manufacturer’s instructions. In
brief, QuikChange reagents, Notch1 vector (100 ng), and
mutagenic primers (Notch 201, 380 ng; Notch 930, 200 ng)
were combined and cycled through the thermal cycling
program indicated in the manufacturer’s protocol. Mu-
tagenic primers were designed to alter the sequence of
the Notch1 39 UTR at the two sites complimentary to
the miR-34a seed sequence (target sites) as specified
by miRDB, TargetScan, and PicTar. Mutant Notch1 39
UTR GoClone vector was amplified and selected per
the manufacturer’s instructions. Plasmids were se-
quenced at The University of Texas at Austin DNA Core
Facility using the following primers: forward, GGGAAGT
ACATCAAGAGCTTCGT, and reverse, CCCCCTGAACCT
GAAACATAAA.
Tumor Sphere Assay
Panc02 cells were seeded in 96-well low-adherence plates
(Corning Inc., Corning, NY) in a serial dilution (from 2,000
to 0 cells per well; six replicates per dilution), as previously
described (23). Cells were cultured under serum-free
conditions using McCoy’s media supplemented with insulin,
B27, N2, EGF, and FGF (all from BD Biosciences, San Jose,
CA) with/without metformin (0.5 mmol/L) or rapamycin
(0.1 mmol/L). Cell media was changed weekly, and tumor
spheres were quantified after 14 days. Pancreatic tumor
spheres (only those with more than five cells per sphere)
were quantified by visual counting at 203 magnification.
The diameter of each tumor sphere was measured using
SPOT software (Diagnostic Instruments, Sterling Heights,
MI). Three independent experiments were performed.
Identification of the CD24+CD44+ Population in
Panc02 Cells
Panc02 cells (;50,000 cells/well) were seeded into six-
well plates (Corning Inc.) and left overnight in a 37°C
incubator at 5% CO2. The following day, cells were washed
with PBS and then treated with fresh complete McCoy’s
media in presence or absence of 0.5 mmol/L metformin.
After 24–72 h of treatment, cells were washed with PBS,
harvested, and stained with anti-mouse antibodies against
phycoerythrin-CD24 and allophycocyanin-CD44 (BD
Pharmigen) as previously described (23). Each antibody
was used at saturating concentrations optimized by initial
titrations for flow cytometry staining. The negative con-
trol panels were mixtures of isotype controls (eBioscience)
diluted to an identical immunoglobulin concentration.
Cells were analyzed using Guava Flow Cytometry (Guava
Technologies, Hayward, CA), and at least 15,000 events
were collected for each sample.
Cell Cycle Analysis
Panc02 cells were treated with complete McCoy’s media in
the presence or absence of either metformin (0.5 mmol/L) or
rapamycin (0.1 mmol/L). Panc02 cells were stained with
propidium iodide (PI) according to the manufacturer’s in-
struction (Guava Cell Cycle Reagent; Millipore). Cells serum
starved for 24 h were used as a control for G0/G1 phase
(quiescent phase). After a 30-min incubation with PI, cells
were analyzed using Guava easyCyte Flow Cytometry. Histo-
grams exhibiting G0/G1, S, and G2/M phases were generated
using ModFit LT Software (Verity Software House, Topsham,
ME). A minimum of three independent experiments were
run in which each condition was tested in six replicates.
Statistical Analysis
All statistics were performed using GraphPad Prism 4
(GraphPad Software, San Diego, CA). One-way ANOVA was
used to assess differences between vehicle and treatment
groups. Two-tailed Student t test was used to assess differ-
ences between vehicle control and an individual treatment
group. Values of P , 0.05 were considered statistically
significant.
RESULTS
Body Weight, Caloric Intake, Glucose Tolerance, and
Serum Factors
An obese phenotype was attained in all mice prior to drug
treatment initiation (15 weeks) as indicated by the increased
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mean body weight (40.8 6 4.7 g) relative to the mean
baseline measurement (20.3 6 29.0 g; P = 0.0005) (Fig.
1A). After just 4 weeks of treatment, metformin signifi-
cantly reduced mean body weight relative to vehicle group
(41.1 6 2.7 g vs. 44.8 6 3.2 g, respectively; P = 0.0062),
whereas rapamycin treatment did not (46.2 6 3.5 g) (Fig.
1A). Despite these varying effects on body weight, the
treatments had no effect on caloric intake (Supplemen-
tary Fig. 1). As expected, the metformin group exhibited
improved glucose clearance (P = 0.027) as well as en-
hanced insulin sensitivity (P = 0.038) relative to vehicle
(Fig. 1B and C). The rapamycin group displayed worsened
glucose sensitivity (P = 0.023), but it did not affect insulin
sensitivity relative to the vehicle group (P = 0.71) (Fig. 1B
and C). Fasting levels of circulating insulin were reduced
in response to metformin treatment (1.9 6 0.8 vs. 2.7 6
0.6 ng/mL; P = 0.03) (Fig. 1D). Mean circulating levels of
the mitogen IGF-1 were nonsignificantly reduced by met-
formin treatment relative to vehicle (400 6 35 vs. 420 6
38 ng/mL; P = 0.08) (Fig. 1E). No statistical differences
were detected between the rapamycin group and the ve-
hicle group regarding insulin (2.6 6 1.1 ng/mL) or IGF-1
(367 6 50 ng/mL) levels. Resistin was decreased in the
metformin group (2.8 6 0.4 vs. 3.8 6 1.5 ng/mL; P =
0.02) as well as in the rapamycin group (2.05 6 0.4 ng/mL)
relative to vehicle (P, 0.001) (Fig. 1F). Serum adiponectin,
relative to control, was significantly increased in the met-
formin group (13.2 6 1.6 vs. 10.5 6 2.3 mg/mL; P = 0.05)
and decreased in the rapamycin group (6.6 6 0.7 mg/mL;
P , 0.001) (Fig. 1G).
Effect of Metformin on Tumor Growth and Intracellular
Signaling Intermediates
At 20 weeks on study, Panc02 cells were injected in the
right flank of mice (n = 15 per group) that continued on
their diet regimen for an additional 4 weeks while tumor
growth was monitored. At study termination, tumors
were collected form mice. Five mice (control, n = 4; met-
formin, n = 1; rapamycin, n = 1) were censored from the
study due to injection errors. Both metformin (0.62 6
0.27 g; P = 0.04) and rapamycin (0.25 6 0.33 g; P ,
0.01) significantly reduced tumor burden compared with
vehicle (0.90 6 0.22 g), although the effect of rapamycin
was more dramatic (Fig. 2A). Metformin (10.6 6 3.5%;
P = 0.006) and rapamycin (19.1 6 5.7%; P = 0.05) both
significantly decreased tumoral mTOR activity, assessed
by measuring phosphorylation of mTOR, relative to un-
treated tumors (43.7 6 8.7%) (Fig. 2B and C). Despite
inhibitory effects on phosphorylation of mTOR, rapamy-
cin treatment (86.3 6 1.9%; P = 0.024), but not metfor-
min treatment (77.2 6 3.3%), resulted in significantly
increased pAkt (Fig. 2B and C). Metformin (53.7 6
3.6%; P = 0.04) and rapamycin (52.6 6 3.2%; P =
0.06) resulted in a mean increase in phosphorylation
of ACC, an inhibitory phosphorylation indicative of
AMPK activity as compared with vehicle (37.9 6 5.6%)
(Fig. 2B and C).
Metformin Increases Expression of miR-34a
Since miRs are aberrantly expressed in many types of
cancers, we screened the expression of miRs highly
regulated in PC during obesity and diabetes (11) using
quantitative real-time PCR (Supplementary Table 1). Val-
idation analysis was performed for those miRs that had P
values #0.15. Validation analysis showed that metformin
significantly increased miR-34a expression (RQ = 2.15 6
1.07 vs. 1.07 6 0.43; P = 0.046) (Fig. 3A) and downregu-
lated Notch (RQ = 0.56 6 0.42 vs. 1.10 6 0.49; P =
0.041) (Fig. 3B), an EMT-associated target of miR-34a
(24–27), relative to untreated/vehicle controls in both
tumors (RQ = 0.61 6 0.07 vs. 1.5.0 6 0.15; P = 0.041)
and in vitro Panc02 cells (RQ = 0.65 6 0.20 vs. 1.13 6
0.09 in untreated cells; P = 0.034). When Panc02 cells
were transfected with Notch reporter plasmid and
a miR-34a mimic, luciferase signal was significantly de-
creased relative to control (P = 0.007) (Fig. 3C), confirm-
ing that Notch is regulated by miR-34a in Panc02 cells.
Moreover, after mutating the two miR-34a target sites
within the Notch 39 UTR in the reporter plasmid, no
effect of miR-34a on luciferase signal was observed (Fig.
3D), indicating that the inhibition of luciferase activity
seen in the Notch + miR-34a condition is due to direct
binding of miR-34a to Notch in Panc02 cells.
Metformin Decreases Expression of Snail, Vimentin,
and Slug in Tumor Samples
Besides Notch, additional EMT markers were found
to be regulated by metformin in tumors. As shown in
Fig. 4, mRNA expression levels of Snail (P = 0.049)
and Vimentin (P = 0.049) were significantly decreased
in the metformin group relative to vehicle. Expression
of Slug was also reduced in response to metformin;
however, this finding only approached significance
(P = 0.059).
Rapamycin Increases Expression of Let-7b in Tumors
and Inhibits Cell Cycle Progression
Let-7b expression in Panc02 tumors was significantly in-
creased in the rapamycin group relative to vehicle controls
(RQ = 1.49 6 0.22 vs. 1.05 6 0.37; P = 0.044) (Fig. 5A).
Metformin had no effect on let-7b expression (0.99 6
0.05; P = 0.88) (Fig. 5A); however, induction of let-7b
expression by metformin has been reported in PC cells
(28). Immunohistochemical staining of downstream cell
cycle regulatory proteins corroborates this finding by dem-
onstrating that rapamycin significantly reduced expression
of cdk4 and cyclin D1 (28.26 3.8%, P, 0.001, and 32.06
4.7%, P = 0.008, respectively) (Fig. 5B and C) relative to
vehicle (43.5 6 4.0 and 48.4 6 3.6%, respectively). Met-
formin had no significant effect on cyclin D1 (39.46 0.9%)
relative to vehicle, although it reduced cdk4 (30.8 6 4.8%;
P , 0.001) (Fig. 5B and C).
Treating Panc02 cells with rapamycin (0.1 mmol/L)
significantly increased the percentage of cells arrested
in the G0/G1 phase of the cell cycle (50.7 6 1.7% of
positive cells) compared with untreated cells (36.4 6
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Figure 1—Effect of metformin versus rapamycin on body weight, insulin sensitivity, and serum hormones in obese/prediabetic mice.
Treatment conditions (n = 15 per group): vehicle (0.1% DMSO in saline), metformin (250 mg/kg), or rapamycin (2.5 mg/kg). Due to
Panc02 cells injection error, 5 mice were censored from the study (vehicle = 11 mice; metformin = 14 mice; rapamycin = 14 mice). A:
Mean body weight, recorded weekly until study termination. Glucose tolerance test (B) and insulin tolerance test (C ) performed prior to
Panc02 cell injection at weeks 19 and 20, respectively (n = 10 per group). Fasting sera harvested at study termination were analyzed for
levels of insulin (D), IGF-1 (E), resistin (F), and adiponectin (G). The bar graph represents mean6 SD. *P< 0.05 by two-tailed Student t test.
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1.0%; P = 0.011) (Fig. 5D and E). Rapamycin also re-
duced the percentage of cells in S phase (10.5 6 0.45%)
compared with untreated cells (21.3 6 1.4%; P = 0.048)
(Fig. 5D and E). No major differences were observed in
the G2/M phase between treatments. Metformin did
not impact cell cycle kinetics relative to untreated cells.
Serum-starved Panc02 cells were used as a positive con-
trol, causing 70% of total cells to arrest in G0/G1 phase.
The decrease in cell cycle progression was not driven by
increased apoptosis, since we did not observe any difference
in the generation of DNA fragments in rapamycin-treated
Panc02 cells compared with untreated cells (Supplemen-
tary Fig. 2).
Metformin Reduced Pancreatic Tumor Sphere
Formation
Since metformin drastically inhibited pancreatic tumor
growth in vivo, we investigated whether this effect was
achieved by acting on CSCs, a population with enhanced
proliferation and self-renewal properties and character-
ized by the expression of the cell surface markers CD24
and CD44 (29). We observed that the CD24+/CD44+ pop-
ulation of Panc02 cells was significantly reduced by met-
formin compared with untreated controls (63.5 6 8.5 vs.
76.7 6 9.4%; P = 0.024) (Fig. 6A and B). Since tumor
sphere–forming capacity has been used to define a more
tumorigenic cell population (29), we grew Panc02 cells
Figure 2—Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A: Scatterplot depicting tumor weights
measured at study termination in mice receiving either metformin (250 mg/kg, n = 14), rapamycin (2.5 mg/kg, n = 14), or vehicle (0.1%
DMSO in saline, n = 11). B and C: Representative images of pancreatic tumors analyzed by immunohistochemical staining of pAkt,
pmTOR, and pACC. C: Quantification of pAkt, pmTOR, and pACC positively stained cells in tumor tissues. Original magnification 340.
Scale bar represents 100 nm. Data are expressed as mean 6 SEM number of positive cells per field in tumors (n = 8 per group). *P <
0.05 by one-way ANOVA.
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into tumor spheres in the presence or absence of metfor-
min and assessed spheroid size and number. After 14 days,
metformin (relative to untreated) significantly reduced
mean size of Panc02 tumor spheres grown under nonad-
herent culture conditions by;50% regardless of initial cell
seeding number (from 500 to 2,000 cells) (Fig. 6C–E). Met-
formin significantly decreased expression of Notch in
tumor spheres (RQ = 0.23 6 0.006 vs. 1.17 6 0.64; P =
0.037) compared with untreated tumor spheres (Fig. 6F).
DISCUSSION
Our findings establish that both metformin and rapamy-
cin inhibit pancreatic tumor growth in a mouse model of
DIO and prediabetes through common and divergent
mechanisms. We found that both pharmacologic agents
blunted the DIO-associated tumoral activation of mTOR,
a crucial complex involved in the regulation of protein
translation. Additional data, however, indicate several
distinct systemic and intracellular effects of metformin
relative to rapamycin, including effects on glucose clear-
ance, circulating levels of energy balance-responsive
hormones and growth factors, miR expression, cell cycle
regulatory protein expression, and stem cell properties.
These findings support epidemiologic data suggesting
that metformin, but not other glucose-lowering therapies,
may decrease PC risk in the prediabetic and diabetic
population as well as minimize PC-related death in
patients with diabetes (6–8). They also provide novel
insights regarding the shared and distinct mechanisms
associated with the anticancer effects of metformin ver-
sus the direct mTOR inhibitor rapamycin.
Figure 3—Metformin induced miR-34a expression in pancreatic tumors through direct binding to Notch. A: Bar graph of miR-34a
expression in pancreatic tumor tissues (n = 6 per group). Data were normalized based on U6 expression. The bar graph represents
mean 6 SEM. *P < 0.05 by two-tailed Student t test. B: Quantification of Notch mRNA expression, relative to b-actin, in tumor samples
and Panc02 cells. The bar graph represents mean 6 SD. *P < 0.05 by two-tailed Student t test. C: Luciferase assay performed on Notch-
transfected Pan02 cells in three independent experiments. D: Luciferase assay performed on mutated Notch-transfected Pan02 cells in
three independent experiments (mutations at two sites in Notch 39 UTR that are complimentary to the miR-34a seed sequence). The bar
graph in C and D represents mean 6 SEM. *P < 0.05 by one-way ANOVA.
Figure 4—Metformin decreased expression of EMT markers in
pancreatic tumors from obese mice. mRNA expression of Snail
(P = 0.049), Vimentin (P = 0.049), and Slug (P = 0.059) in tumors
treated with metformin (250 mg/kg) and vehicle (0.1% DMSO in
saline) (n = 6 per group). The bar graph represents mean 6 SEM.
*P < 0.05 by Student t test.
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We have previously shown that rapamycin exerts
significant tumor growth inhibitory effects in association
with diminished mTOR signaling in normoweight mice
injected with the same Panc02 tumors used in the present
studies (20). In the current report, we show this growth-
prohibitive effect of rapamycin in the context of obesity and
insulin resistance. Additionally, these findings suggest that
a potential mechanism for the inhibitory effects of rapamy-
cin is the increase in let-7b, an miR involved in the regula-
tion of cell proliferation and differentiation, at least in part
through regulation of cell cycle regulatory proteins (30–32).
In fact, rapamycin treatment resulted in reduced expres-
sion of cdk4 and cyclin D1. The composite effect of these
outcomes in response to rapamycin treatment was cell
cycle inhibition, as evidenced by an accumulation of cells
in G0/G1, a finding corroborated by others (33,34).
Specific mTOR inhibition with rapamycin resulted in
tumor growth suppression but, unfortunately, was also
accompanied by decreased insulin responsiveness and hy-
perglycemia, consistent with previous reports (35). In con-
trast, metformin significantly blunted pancreatic tumor
growth (albeit to a lesser extent than rapamycin) without
Figure 5—Rapamycin increased let-7b level in pancreatic tumors and inhibited cell cycle progression. A: Bar graph representing mean let-
7b mRNA expression in tumor tissues (n = 3–6 per group). The bar graph represents mean 6 SEM. *P < 0.05 by Student t test. B and C:
Representative images of tumors immunohistochemically stained for the cell cycle regulatory proteins cdk4 and cyclin D1 (B) and re-
spective quantification of positively stained cells (n = 8 per group) (C). Scale bar represents 100 nm. D: Cell cycle analysis (PI staining) of
Panc02 cells treated with metformin (0.5 mmol/L) or rapamycin (0.1 mmol/L) for 24 hours (n = 3 per treatment in six replicates). Values within
each cell cycle phase with different letters (a,b) or symbols (#,*) are significantly different at P< 0.05. E: Histogram representation of the cell
cycle phase distribution. The bar graph represents mean 6 SEM. *P < 0.05 by one-way ANOVA. The white sphere in B (CND1 expression
for the rapamycin-treated group) is the cellular outline of a large adipocyte because histological processing with organic solvents extracts
the lipid content of cells.
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apparent adverse metabolic effects, similar to previous obser-
vations (36). In our study, we found that metformin resulted
in improved glucose and insulin metabolism and a serum
profile (decreased IGF-1, insulin, and resistin; increased adi-
ponectin) associated with normalization of metabolic state
and tumor growth inhibition in DIO mice (20,37,38). Similar
to previous reports (39), we found that metformin induced
tumoral expression of miR-34a, an miR typically lost during
cancer progression, including pancreatic (24,40), and has
been shown to contribute to reduced survivability in those
diagnosed with PC (41). miR-34a suppresses EMT by acting
as a negative regulator of the signaling pathway activated
by transforming growth factor-b (TGF-b), a master regu-
lator of EMT (42). Interestingly, metformin has been
shown to inhibit TGF-b–induced EMT in breast cancer
cells, particularly stem cell–enriched populations, as well
as alter expression of EMT mediators (43). Expression of
these mediators, such as Snail, is intimately linked to
TGF-b signaling and miR-34a expression. Specifically, as
TGF-b increases, expression of miR-34a is diminished and
Snail is enhanced (42), whereas re-expression of miR-34a
reduces expression of Snail and other EMT mediators
such as Notch and Slug (44). Our in vitro results corrob-
orated these findings by demonstrating that targeted
binding of miR-34a regulated expression of Notch in
Panc02 cells, further suggesting that metformin may
modulate EMT-related targets, such as Notch, in a miR-
34a–dependent manner in Panc02 tumors. Panc02 tumor
Figure 6—Metformin decreased tumor sphere formation and EMT-associated gene expression in vitro. Distribution (A) and quantification
(B) of the CD24+CD44+ population in Panc02 cells treated with metformin (0.5 mmol/L) for 24 h (P = 0.024). Representative image of Panc02
cells treated with metformin (0.5 mmol/L) for 14 days (C), quantification of the mean diameter (D), and number of tumor spheres of Panc02
cells treated with metformin (0.5 mmol/L) for 14 days (E), relative to untreated control cells. F: Bar graph representing Notch mRNA
expression in pancreatic tumor spheres treated with metformin (0.5 mmol/L) or control after 14 days of treatment (n = 3 per treatment
in six replicates). The bar graph represents mean 6 SD. *P < 0.05 by Student t test.
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spheres also had reduced Notch expression in response to
metformin. Dysregulation of Notch signaling, a targeted
perturbation in many cancer types (24,45), has been
shown to enhance hypoxia-induced tumor cell migration
and invasion and influence expression of Snail and Slug
(46,47). Additionally, metformin reduced the CD24+/CD44+
cell population and decreased the tumor sphere–forming
capacity of Panc02 cells, corroborating previous findings
that metformin significantly reduced CSC enrichment in pan-
creatic tumors (28). The importance of this TGF-b/miR-34a
pathway cannot be understated in the context of Panc02
cells, which have a mutation in Smad4 (a downstream
regulator of TGF-b signaling), a genetic anomaly that is
found in ;55% of all pancreatic ductal adenocarcinomas
and is predictive of poor prognosis (48). Loss of Smad
functioning can alter miR expression profiles (49), but
metformin, in our study, overcame the loss of miR-34a.
This suggests that metformin may be able to blunt the
protumorigenic nature of genetic alterations such as
Smad4 mutation, possibly in part through negatively reg-
ulating the EMT.
In summary, these preclinical findings suggest metfor-
min and rapamycin can both inhibit diabetes-associated
pancreatic tumor growth through common and distinct
miR-mediated mechanisms. We conclude that metformin
and direct mTOR inhibitors, alone or possibly in combi-
nation, represent promising interventions that should be
tested in future translational studies evaluating new
strategies for breaking the diabetes-PC link.
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